Subtype
Lung Carcinoma
CI-CAN-00001086Explore in graph →
2,130 active trials51 approved drugs598 evidence items
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001086Explore in graph →
Clinical trials
7,791 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,177)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05206812 | Window of Opportunity Trial of Durvalumab (MEDI4736) to Identify Immune Dynamics in Operable Non-small Cell Lung Cancer (NSCLC) (MIRACLE) | active not recruiting | Phase 2 | 25 | Yonsei UniversityOTHER | 1 | Jan 27, 2026 | clinicaltrials |
| NCT05786430 | Lazertinib+Pemetrexed/Carboplatin in Patients With EGFR Sensitizing Mutation Positive Recurrent or Metastatic Non-Small Cell Lung Cancer Failed to Prior Lazertinib(LUCAS) | active not recruiting | Phase 2 | 87 | Yonsei UniversityOTHER | 1 |
| Jan 27, 2026 |
| clinicaltrials |
| NCT05816252 | A Study of SKB264 (MK-2870; Sac-TMT) for the Treatment of Participants With Advanced or Metastatic Non-small Cell Lung Cancer (SKB264-II-04) (MK-2870-003) | active not recruiting | Phase 2 | 356 | Klus Pharma Inc.INDUSTRY | 6 | Jan 27, 2026 | clinicaltrials |
| NCT05601973 | Amivantamab, Lazertinib and Bevacizumab in Patients With EGFR-mutant Advanced Non-small Cell Lung Cancer With Progression on Previous Third-generation EGFR-TKI(AMAZE-lung) | active not recruiting | Phase 2 | 60 | ETOP IBCSG Partners FoundationNETWORK | 6 | Jan 21, 2026 | clinicaltrials |
| NCT04743505 | Safety and Efficacy of Combining APL-101 With Frontline Osimertinib in Patients With EGFR-mutated Metastatic Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 27 | Washington University School of MedicineOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT05740943 | Induction Lorlatinib in Stage III Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 48 | Guangdong Provincial People's HospitalOTHER | 1 | Jan 20, 2026 | clinicaltrials |
| NCT06879717 | A Study of Roginolisib (IOA-244) in Combination With Dostarlimab With or Without Docetaxel in Metastatic Non Small-cell Lung Cancer (NSCLC) Patients(PULMO-01) | active not recruiting | Phase 1 / Phase 2 | 45 | iOncturaINDUSTRY | 3 | Jan 16, 2026 | clinicaltrials |
| NCT03228667 | QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | active not recruiting | Phase 2 | 40 | ImmunityBio, Inc.INDUSTRY | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05089916 | Radiation During Osimertinib Treatment: a Safety and Efficacy Cohort Study(ROSE) | active not recruiting | Phase 2 | 42 | AIO-Studien-gGmbHOTHER | 1 | Jan 14, 2026 | clinicaltrials |
| NCT05074810 | Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients(RAMP203) | active not recruiting | Phase 1 / Phase 2 | 153 | Verastem, Inc.INDUSTRY | 6 | Jan 12, 2026 | clinicaltrials |
| NCT04919811 | Taletrectinib Phase 2 Global Study in ROS1 Positive NSCLC(TRUST-II) | active not recruiting | Phase 2 | 217 | Nuvation Bio Inc.INDUSTRY | 9 | Jan 7, 2026 | clinicaltrials |
| NCT02638090 | Pembro and Vorinostat for Patients With Stage IV Non-small Cell Lung Cancer (NSCLC) | active not recruiting | Phase 1 / Phase 2 | 120 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 22, 2025 | clinicaltrials |
| NCT07274761 | Neoadjuvant Sunvozertinib in Stage II-IIIB Non-small Cell Lung Cancer Harboring EGFR Exon 20 Insertion Mutation. | active not recruiting | Phase 2 | 24 | Shanghai Pulmonary Hospital, Shanghai, ChinaOTHER | 1 | Dec 10, 2025 | clinicaltrials |
| NCT04625647 | Testing the Use of Targeted Treatment (AMG 510) for KRAS G12C Mutated Advanced Non-squamous Non-small Cell Lung Cancer (A Lung-MAP Treatment Trial) | active not recruiting | Phase 2 | 116 | SWOG Cancer Research NetworkNETWORK | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT04940325 | Datopotamab Deruxtecan (Dato-DXd, DS-1062a) in Advanced and/or Unresectable Non-Small Cell Lung Cancer(ICARUS-LUNG01) | active not recruiting | Phase 2 | 100 | Gustave Roussy, Cancer Campus, Grand ParisOTHER | 1 | Nov 26, 2025 | clinicaltrials |
| NCT05781308 | Combination of Paclitaxel-bevacizumab ± Atezolizumab in Patients With Advanced NSCLC Progressing After Immunotherapy & Chemotherapy(ADAPTABLE) | active not recruiting | Phase 2 | 156 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT04180371 | Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression | active not recruiting | Phase 1 / Phase 2 | 288 | BicycleTx LimitedINDUSTRY | 5 | Nov 17, 2025 | clinicaltrials |
| NCT05200481 | Study of Safety and Efficacy of Brigatinib Plus Chemotherapy or Brigatinib Only in Advanced ALK-Positive Lung Cancer (MASTERPROTOCOL ALK)(MP-ALK) | active not recruiting | Phase 2 | 110 | Intergroupe Francophone de Cancerologie ThoraciqueOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT03672773 | Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 35 | Jonsson Comprehensive Cancer CenterOTHER | 1 | Nov 10, 2025 | clinicaltrials |
| NCT04074967 | Study of ARRY-614 Plus Either Nivolumab or Nivolumab+Ipilimumab | active not recruiting | Phase 1 / Phase 2 | 70 | Dan ZandbergOTHER | 1 | Nov 6, 2025 | clinicaltrials |
| NCT03539536 | Study of Telisotuzumab Vedotin (ABBV-399) in Participants With Previously Treated c-Met+ Non-Small Cell Lung Cancer | active not recruiting | Phase 2 | 270 | AbbVieINDUSTRY | 26 | Nov 5, 2025 | clinicaltrials |
| NCT03667820 | Study of Osimertinib and Stereotactic Ablative Radiation (SABR) in EGFR Mutant NSCLC | active not recruiting | Phase 2 | 41 | University of Texas Southwestern Medical CenterOTHER | 1 | Nov 4, 2025 | clinicaltrials |
| NCT03334617 | Phase II Umbrella Study of Novel Anti-cancer Agents in Participants With NSCLC Who Progressed on an Anti-PD-1/PD-L1 Containing Therapy(HUDSON) | active not recruiting | Phase 2 | 528 | AstraZenecaINDUSTRY | 8 | Oct 27, 2025 | clinicaltrials |
| NCT04397003 | Personalized Neoantigen Vaccine in Combination With Durvalumab (MEDI4736) in Extensive Stage Small Cell Lung Cancer | active not recruiting | Phase 2 | 6 | Washington University School of MedicineOTHER | 1 | Oct 22, 2025 | clinicaltrials |
| NCT05565417 | Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas | active not recruiting | Phase 1 / Phase 2 | 67 | Immunitas TherapeuticsINDUSTRY | 1 | Oct 16, 2025 | clinicaltrials |
| NCT00977470 | Erlotinib With or Without Hydroxychloroquine in Chemo-Naive Advanced NSCLC and (EGFR) Mutations | active not recruiting | Phase 2 | 76 | Massachusetts General HospitalOTHER | 1 | Oct 15, 2025 | clinicaltrials |
| NCT04931654 | A Study to Assess the Safety and Efficacy of AZD7789 in Participants With Advanced or Metastatic Solid Cancer | active not recruiting | Phase 1 / Phase 2 | 136 | AstraZenecaINDUSTRY | 10 | Oct 9, 2025 | clinicaltrials |
| NCT04931017 | Metformin for Chemoprevention of Lung Cancer in Overweight or Obese Individuals at High Risk for Lung Cancer | active not recruiting | Phase 2 | 50 | Northwestern UniversityOTHER | 2 | Oct 7, 2025 | clinicaltrials |
| NCT04472949 | Thoracic Radiotherapy Plus Maintenance Durvalumab After First Line Carboplatin and Etoposide Plus Durvalumab in Extensive-stage Disease Small Cell Lung Cancer (ED-SCLC). | active not recruiting | Phase 2 | 46 | Swiss Cancer InstituteOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT05949619 | A Study of BL-M02D1 in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer or Other Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05020457 | SI-B001 Combined With Chemotherapy in the Treatment of EGFR/ALK WT Recurrent or Metastatic NSCLC. | active not recruiting | Phase 2 | 69 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT05020769 | SI-B001 Combined With Osimertinib Mesylate Tablets in the Treatment of Recurrent Metastatic Non-small Cell Lung Cancer. | active not recruiting | Phase 2 / Phase 3 | 14 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 26, 2025 | clinicaltrials |
| NCT06448910 | Cadonilimab(AK104) Plus Concurrent Chemoradiotherapy in Patients With Locally Advanced, Unresectable, Stage III NSCLC | active not recruiting | Phase 2 | 41 | Fudan UniversityOTHER | 1 | Sep 24, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT05880706 | A Study of BL-B01D1 and BL-B01D1 in Combination With Osimertinib Mesylate Tablets in Patients With Locally Advanced or Metastatic Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 198 | Sichuan Baili Pharmaceutical Co., Ltd.INDUSTRY | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT03647163 | Ph I/II Trial of Systemic VSV-IFNβ-NIS in Combination With Checkpoint Inhibitor Therapy in Patients With Select Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 33 | Vyriad, Inc.INDUSTRY | 1 | Sep 16, 2025 | clinicaltrials |
| NCT06020066 | SRS for NSCLC With Oligo-residual Intracranial Disease After First-line 3rd Generation EGFR-TKI | active not recruiting | Phase 2 | 202 | Fudan UniversityOTHER | 1 | Sep 15, 2025 | clinicaltrials |
| NCT07145333 | Pharmacogenomics ANDA SNP Clinical Study - Topotecan and Single Nucleotide Polymorphisms(Drug-SNP) | active not recruiting | Phase 2 / Phase 3 | 600 | Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB ChairINDUSTRY | 1 | Sep 8, 2025 | clinicaltrials |
| NCT05318573 | A Study to Evaluate Safety, Efficacy of FF-10832 in Combo With Pembrolizumab in Urothelial & Non-small Cell Lung Cancer | active not recruiting | Phase 2 | 120 | Fujifilm Pharmaceuticals U.S.A., Inc.INDUSTRY | 1 | Sep 4, 2025 | clinicaltrials |
| NCT05585320 | A Phase 1/2a Study of IMM-1-104 in Participants With Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 209 | Immuneering CorporationINDUSTRY | 1 | Sep 2, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT05796089 | Chemotherapy and Immunotherapy in Extensive-Stage Small-Cell Lung Cancer With Thoracic Radiotherapy(CHEST RT) | active not recruiting | Phase 2 | 35 | Trans Tasman Radiation Oncology GroupOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT04495153 | CAN-2409 Plus Prodrug With Standard of Care Immune Checkpoint Inhibitor for Stage III/IV NSCLC | active not recruiting | Phase 2 | 90 | Candel Therapeutics, Inc.INDUSTRY | 1 | Aug 22, 2025 | clinicaltrials |
| NCT03620669 | 1st Line Durvalumab in PS 2 NSCLC Patients | active not recruiting | Phase 2 | 48 | Swiss Cancer InstituteOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT05787613 | A Clinical Study to Evaluate the Efficacy and Safety of HLX26 (Anti-LAG-3 Monoclonal Antibody Injection) Combined With Serplulimab and Chemotherapy in Previously Untreated Advanced NSCLC Patients | active not recruiting | Phase 2 | 132 | Shanghai Henlius BiotechINDUSTRY | 1 | Aug 6, 2025 | clinicaltrials |
| NCT05078931 | A Study to Evaluate Pembrolizumab Plus Lenvatinib in PD-L1 Positive TKI Resistant NSCLC Patients | active not recruiting | Phase 2 | 35 | Shanghai Chest HospitalOTHER | 1 | Jul 30, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Jan 27, 2026source: clinicaltrials